Immunotherapy and targeted therapy before esophageal cancer surgery
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two drugs—cadonilimab (an immunotherapy) and anlotinib (a targeted therapy)—given before surgery for advanced esophageal cancer that can still be removed. The goal is to see if this combination helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of esophageal cancer called squamous cell carcinoma that is advanced but can still be removed by surgery (stage II to IVA).
- You have not had any prior treatment for this specific cancer, like chemotherapy or radiation.
- You are healthy enough that your doctors believe surgery to remove the cancer is possible.
- You must be 18 years or older and willing to provide a tissue sample from a previous biopsy or have a new one taken.
- You have not taken any immunotherapy drugs (such as PD-1 inhibitors) before.
- You are not pregnant and agree to use effective birth control during the study and for at least 120 days after the last treatment dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
Hear when a new Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.